Loading...
Market
Will AstraZeneca's Imfinzi become the standard of care for muscle-invasive bladder cancer by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical guidelines updates from major oncology societies like ASCO or ESMO
Story
AstraZeneca's Imfinzi Shows Promise in Bladder Cancer Treatment
Sep 15, 2024, 02:35 PM
AstraZeneca's Imfinzi (durvalumab) has shown promising results in treating muscle-invasive bladder cancer. In the NIAGARA Phase III trial, the perioperative regimen of Imfinzi reduced the risk of recurrence by 32% and the risk of death by 25% compared to neoadjuvant chemotherapy alone. These findings suggest that Imfinzi could potentially extend the lives of bladder cancer patients and open up a new market for the blockbuster medicine. The study's results were highlighted at the ESMO 2024 conference.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Yes • 50%
No • 50%
